| Literature DB >> 30519213 |
Sung Hyuk Heo1, Dongwhane Lee1, Yong Chul Kwon1, Bum Joon Kim1, Kyung Mi Lee2, Cheryl D Bushnell3, Dae-Il Chang1.
Abstract
Background: Some patients with acute stroke symptoms do not show hyperintensities on diffusion-weighted image (DWI). A few case reports have indicated that acutely developed cerebral microbleeds (CMBs) might cause focal symptoms. This study sought to investigate the incidence and characteristics of symptomatic CMBs in the patients with acute stroke symptoms but without DWI ischemic lesions.Entities:
Keywords: cerebral microbleeds; diffusion weighted image; magnetic resonance image; stroke; transient ischemic attack
Year: 2018 PMID: 30519213 PMCID: PMC6258787 DOI: 10.3389/fneur.2018.00988
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Baseline demographic and clinical characteristics.
| Men, n (%) | 102 (56.7) | 20 (51.3) | 14 (87.5) | 0.038 |
| Age | 61.3 ± 12.6 | 66.5 ± 9.7 | 65.7 ± 9.8 | 0.030 |
| Previous stroke, n (%) | 20 (11.1) | 20 (51.3) | 4 (25.0) | < 0.001 |
| Previous antithrombotics, n (%) | 19 (10.6) | 12 (30.8) | 2 (12.5) | 0.004 |
| Hypertension, n (%) | 99 (55.0) | 27 (69.2) | 11 (68.8) | 0.179 |
| Diabetes, n (%) | 37 (20.6) | 9 (23.1) | 4 (25.0) | 0.876 |
| Dyslipidemia, n (%) | 73 (40.6) | 14 (35.9) | 6 (37.5) | 0.851 |
| Current smoker, n (%) | 39 (21.7) | 6 (15.4) | 4 (25.0) | 0.623 |
| Atrial fibrillation, n (%) | 2 (1.1) | 2 (5.1) | 0 (0.0) | 0.234 |
| BMI (kg/m2) | 24.3 ± 3.1 | 23.6 ± 2.8 | 24.0 ± 3.0 | 0.393 |
| Glucose (mg/dl) | 114.9 ± 50.7 | 111.5 ± 30.7 | 108.6 ± 27.4 | 0.833 |
| HbA1c (%) | 5.9 ± 1.0 | 6.0 ± 0.8 | 5.8 ± 0.8 | 0.714 |
| Total cholesterol (mg/dl) | 178.9 ± 38.8 | 170.6 ± 42.3 | 177.9 ± 41.7 | 0.494 |
| HDL cholesterol (mg/dl) | 45.3 ± 12.6 | 43.8 ± 12.9 | 42.8 ± 11.6 | 0.633 |
| TG cholesterol (mg/dl) | 127.7 ± 80.2 | 114.8 ± 64.2 | 116.4 ± 59.6 | 0.593 |
| Systolic BP (mmHg) | 143.7 ± 24.7 | 142.6 ± 27.6 | 143.3 ± 25.9 | 0.970 |
| Diastolic BP (mmHg) | 85.9 ± 10.6 | 85.4 ± 11.4 | 81.5 ± 11.6 | 0.306 |
| Modified Fazekas scale (median, IQR) | 1 (0,1) | 1 (1,2) | 1 (1,2) | < 0.001 |
| ABCD2 score (median, IQR) | 4 (3,5) | 5 (4, 6) | 4 (4, 5) | 0.003 |
| Length of stay (median, IQR), days | 3 (2,5) | 4 (3, 6) | 4 (2, 5) | 0.051 |
| Admission NIHSS (median, IQR) | 0 (0, 2) | 2 (0, 4) | 2.5 (1, 4) | < 0.001 |
| Discharge NIHSS (median, IQR) | 0 (0, 0) | 0 (0, 2) | 0 (0, 2.5) | < 0.001 |
| Discharge mRS (median, IQR) | 0 (0, 0) | 1 (0, 1) | 1 (0, 1) | < 0.001 |
P-values are for Chi-squared test unless indicated.
P-value is for ANOVA.
.
P-value is for Kruskal-Wallis test.
BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high-density cholesterol; TG, triglyceride; BP, blood pressure; IQR, interquartile range; NIHSS, NIH stroke scale; mRS, modified Rankin scale.
Summary of acute stroke symptoms and cerebral microbleeds in the relevant areas in 16 patients.
| 1 | M | 66–70 | HT, DM, HL | Pure sensory | > 24 h | 5 | Thalamus | 4 | (+) | 0.47 ± 0.05 | 1.53 | (+) | 9 (1/8) |
| 2 | M | 76–80 | HT | Ataxic hemiparesis | < 24 h | 4 | pons | 3 | (+) | 0.39 ± 0.03 | 0.94 | (+) | 5 (0/5) |
| 3 | M | 76–80 | HT, AF, smoking | Dysarthria | > 24 h | 4 | Subcortex | 7 | (+) | 1.05 ± 0.12 | 3.12 | (+) | 10 (5/5) |
| 4 | M | 71–75 | HT, DM, HL | Pure motor | > 24 h | 7 | Subcortex | 7 | (+) | 0.46 ± 0.03 | 1.53 | (–) | 3 (2/1) |
| 5 | M | 56–60 | HT, HL, smoking | Pure motor | < 24 h | 4 | Internal capsule | 2 | (+) | 0.39 ± 0.04 | 1.45 | (–) | 1 (0/1) |
| 6 | M | 56–60 | Smoking | Pure sensory | > 24 h | 4 | Pons | 2 | (+) | 0.38 ± 0.08 | 1.55 | (–) | 5 (0/5) |
| 7 | M | 71–75 | HT, HL | Dysarthria, ataxia | < 24 h | 4 | Cerebellum | 8 | (+) | 0.89 ± 0.50 | 2.66 | (–) | 2 (2/0) |
| 8 | M | 66–70 | HT | Dysarthria, facial palsy | > 24 h | 3 | Subcortex | 2 | (+) | 0.77 ± 0.11 | 3.09 | (+) | 2 (0/2) |
| 9 | M | 71–75 | HL, smoking | Pure motor | < 24 h | 6 | Subcortex | 5 | (+) | 0.42 ± 0.03 | 1.57 | (+) | 3 (1/2) |
| 10 | F | 61–65 | None | Dysarthria | < 24 h | 4 | Subcortex | 5 | (+) | 0.81 ± 0.10 | 2.85 | (–) | 1 (0/1) |
| 11 | M | 51–55 | HT, DM, HL, smoking | Pure motor | > 24 h | 6 | Pons | 4 | (+) | 0.76 ± 0.12 | 3.06 | (–) | 4 (1/3) |
| 12 | M | 71–75 | HT, HL | Ataxic hemiparesis | > 24 h | 4 | Thalamus | 8 | (+) | 0.42 ± 0.04 | 1.49 | (+) | 13 (3/10) |
| 13 | M | 51–55 | HT | Pure motor | < 24 h | 5 | Pons | 3 | (–) | (+) | 3 (0/3) | ||
| 14 | M | 61–65 | HT, DM | Ataxia | < 24 h | 5 | Cerebellum | 3 | (–) | (–) | 1 (1/0) | ||
| 15 | M | 41–45 | HT, HL | Pure motor | < 24 h | 4 | Thalamus | 3 | (–) | (–) | 1 (0/1) | ||
| 16 | F | 66–70 | HT | Diplopia | < 24 h | 3 | Midbrain | 2 | (–) | (–) | 1 (0/1) |
ADC, apparent deficiency coefficient; CSF, cerebrospinal fluid; CMB, cerebral microbleed; M, male; F, female; HT, hypertension; DM, diabetes mellitus; HL, hyperlipidemia; AF, atrial fibrillation.
Figure 1Diffusion-weighted images (A,B) and gradient-echo sequences (C,D) show suspicious symptomatic cerebral microbleeds with (patient 1, A,C) or without (patient 13, B,D) the hyperintense rim in the patients.